Search
Research
Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trialWe tested if disrupting iron utilisation by P. aeruginosa by adding the Tris-buffered chelating agent CaEDTA to nebulised tobramycin would enhance bacterial clearance and improve lung function in CF patients.
Research
Changes in airway inflammation with pseudomonas eradication in early cystic fibrosisNeutrophil elastase is a significant risk factor for structural lung disease in cystic fibrosis, and Pseudomonas aeruginosa airway infection is linked with neutrophilic inflammation and substantial respiratory morbidity. We aimed to evaluate how neutrophil elastase (NE) activity changes after P. aeruginosa eradication and influences early disease outcomes. We assessed participants in the AREST CF cohort between 2000 and 2018 who had P. aeruginosa cultured from their routine annual bronchoalveolar lavage (BAL) fluid and who underwent eradication treatment and a post eradication BAL. Factors associated with persistent P. aeruginosa infection, persistent neutrophilic inflammation following eradication and worse structural lung disease one year post-eradication were evaluated.
Please contact the team early (at the stage of project design and budgeting) to ensure the most appropriate physiological test is selected with adequate funding.
Learn more about the Focus areas for the Wal-yan Respiratory Centre
The Artificial Intelligence team at the Wal-yan Respiratory Research Centre is dedicated to delivering AI solutions for major challenges in respiratory healthcare and research.
Respiratory illness accounts for 12% of the age-standardised gap in mortality between Indigenous and non-Indigenous Australians.
The Wal-yan Respiratory Research Centre is made up of multi-disciplinary teams that are committed to improving the lives of children and their families living with respiratory disease.
News & Events
New study to find COVID-fighting properties in existing medications thanks to national grantNearly 50 existing prescription medications already used by Australians will be tested by new research in the fight against COVID’s mutant variants.
News & Events
300th participant recruited to crucial respiratory research programA research program, which enables over 25 important respiratory research studies to be undertaken, celebrated the recruitment of its 300th participant on 14 December 2022.
News & Events
Research to help identify which children will develop asthma and to design more specific asthma treatments supported by Federal Government fundingResearch focussed on identifying which children will develop asthma, and developing more specific asthma treatments, has been supported by the National Health and Medical Research Council’s (NHMRC) Ideas Grants announced by the Federal Government on 14 December 2022.